Blog

Investment from largest shareholder strengthens balance sheet, signals insider conviction, and funds Telomir-1’s upcoming IND submission for a rare disease indication

MIAMI, FLORIDA / ACCESS Newswire / May 21, 2025 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) (“Telomir” or the “Company”), an emerging leader in age-reversal science, today announced it has secured $3 million in equity financing, through a direct investment by The Bayshore Trust, the Company’s largest shareholder.

The transaction involved the purchase of 1 million restricted shares of the Company’s common stock at $3.00 per share, representing an 18% premium to Telomir’s closing share price of $2.54 on the date of execution. The transaction was structured as a straight restricted common stock transaction with no warrants, no discounts, and no convertible features.

This transaction follows a prior $1 million equity investment at $7.00 per share made on December 9, 2024, through The Starwood Trust-an entity affiliated with the Company’s largest shareholder – and complements an existing $5 million non-dilutive line of credit from the same affiliated group, which remains undrawn.

“We’ve now raised $4 million in equity and secured a $5 million credit line – all through affiliated entities on shareholder-friendly terms,” said Erez Aminov, Chairman and CEO of Telomir. “These investments included no warrants, no discounts, and no toxic structures. Every financing decision we make is grounded in a long-term view of shareholder value, and this raise reflects that discipline.”

From an operational standpoint, our first goal is to submit our IND by year-end and generate early human efficacy data in the most efficient and capital-responsible way. We believe pursuing a rare disease indication gives us a strategic entry point to demonstrate clinical impact and build broader value.

Advancing a Growing Pipeline with Breakthrough Potential

Telomir is advancing two highly innovative drug candidates: Telomir-1, a first-in-class age-reversal molecule targeting the root causes of cellular decline, and Telomir-Ag2, a stabilized Silver(II) compound designed to address the growing threat of drug-resistant infections.

Telomir-1: Reversing Aging, Treating Disease, and Extending Longevity

Telomir-1 is an oral small molecule that addresses five fundamental biological drivers of aging and chronic disease: mitochondrial dysfunction, oxidative stress, calcium imbalance, toxic metal accumulation (iron and copper), and telomere shortening.

In preclinical models, Telomir-1 has demonstrated:

• Reversal of the biological clock, improving both lifespan and health span

• Improvement of mitochondrial energy production in metabolically stressed cells

• Reduction of oxidative stress (ROS), a key contributor to age-related damage

• Correction of calcium signaling pathways associated with neurodegeneration and cell death

• Protection against metal-induced toxicity from iron and copper

• Telomere lengthening and stabilization to support cellular regeneration

Therapeutic potential has been demonstrated across several critical indications:

• Progeria: Telomir confirms lifespan restoration and normalization of accelerated aging in a preclinical model of Progeria, a rare genetic disorder causing rapid aging

• Type 2 diabetes: Telomir-1 reversed insulin resistance, lowered fasting glucose, and improved glucose homeostasis in zebrafish models

• Wilson’s disease: Telomir-1 protected cells from copper-induced toxicity, restoring mitochondrial function and reducing oxidative stress

• Oncology: In a prostate cancer mice model, Telomir-1 reduced tumor volume by approximately 50%

• Chemotherapy support: Co-administration with Paclitaxel prevented mortality in animals otherwise experiencing toxicity

• Retinal and neural protection: In vitro studies showed strong protection of human retinal cells from oxidative and metal stress conditions

These results support the advancement of Telomir-1 in multiple rare and high-value indications, including:

• Progeria and Werner Syndrome

• Wilson’s Disease

• Type 2 Diabetes

• Autism Spectrum Disorder (ASD)

• Spasmodic Dysphonia (SD)

• Age-related Macular Degeneration (AMD)

Telomir plans to engage with the FDA through the Rare Disease Endpoint Advancement (RDEA) Pilot Program, which supports the development of novel clinical endpoints for underserved conditions. In parallel, the Company is advancing a rare disease indication aligned with Telomir-1’s mechanism of action to efficiently generate early human efficacy data and support broader clinical development.

Telomir-Ag2: Stabilized Silver(II) for Drug-Resistant Infections

Telomir-Ag2 is a novel Silver(II) complex stabilized using Telomir’s proprietary chelation platform. Silver(II) has historically shown strong antimicrobial potential but has remained clinically impractical due to its instability-until now.

Preclinical studies demonstrate that Telomir-Ag2 is active against:

• Escherichia coli

• Pseudomonas aeruginosa

• Enterococcus faecalis

• Staphylococcus aureus

• Methicillin- and aminoglycoside-resistant Staphylococcus aureus (MARSA)

Key features include:

• Superior antimicrobial performance over Silver(I) in minimum inhibitory concentration (MIC) assays

• No sulfa-based compounds, minimizing allergic and cytotoxic risks

• Broad potential as a topical product across burn treatment, wound care, and surgical infection prevention

Telomir-Ag2 addresses a growing global market projected to exceed $30 billion across antimicrobial dressings, hospital-acquired infection prevention, and wound care.

“Telomir-Ag2 may be the first stabilized Silver(II) compound viable for medical use,” said Dr. Itzchak Angel, Chief Scientific Advisor of the Company. “It’s broad-spectrum activity, especially against resistant strains, represents a major advancement in antimicrobial science.”

Cautionary Note Regarding Forward-Looking Statements

This press release, statements of Telomir’s management or advisors related thereto, and the statements contained in the news story linked in this release contain “forward-looking statements,” which are statements other than historical facts made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These risks and uncertainties include, but are not limited to, the potential use of the data from our studies, our ability to develop and commercialize Telomir-1 for specific indications, and the safety of Telomir-1.

Any forward-looking statements in this press release are based on Telomir’s current expectations, estimates and projections only as of the date of this release. These risks and uncertainties include, but are not limited to, the potential use of the data from our studies, our ability to develop and commercialize Telomir-1 for specific indications and safety of Telomir-1. These and other risks concerning Telomir’s programs and operations are described in additional detail in its Annual Report on Form 10-K for the fiscal year ended December 31, 2024, which is on file with the SEC. Telomir explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.

Contact Information

Helga Moya
info@telomirpharma.com
(786) 396-6723

SOURCE: Telomir Pharmaceuticals, Inc

View the original press release on ACCESS Newswire

Acquisition strengthens nationwide telehealth coverage, advancing access to critical and specialized care for hospitals nationwide

NEW YORK CITY, NY / ACCESS Newswire / May 21, 2025 / Equum Medical, one of the nation’s leading providers of acute telehealth-enabled clinical workforce solutions, today announced it has acquired the clinical health services of VeeOne Health, including its Tele-Psychiatry, Tele-Neurology, Tele-Infectious Disease (Tele-ID), Tele-Pulmonary and Tele-ICU service lines. This strategic acquisition expands Equum’s comprehensive telehealth offerings across the care continuum and reinforces its recognized market leadership in acute care telehealth. The combined entity now will support physician service coverage in over 200 hospitals and post-acute facilities nationwide.

With the addition of VeeOne’s capabilities, Equum accelerates its mission to improve healthcare access and outcomes for hospitals and health systems. Tele-Psychiatry services will enable partner hospitals to provide 24/7 emergency and acute psychiatric care virtually, addressing the nationwide shortage of mental health specialists. Likewise, Tele-Neurology services (including on-demand stroke neurologists and other neuro-specialists) will allow rapid neurological consultations in emergency and acute settings, ensuring patients receive timely expert care regardless of location.

Dr. Corey Scurlock, CEO and Founder of Equum Medical, stated, “The acquisition of VeeOne Health’s services represents an exciting opportunity to continue expanding the reach and depth of Equum’s acute care telehealth offerings. By adding these critical service lines, Equum further solidifies its position as a comprehensive partner to hospitals nationwide. We are committed to ensuring that our expanded services bring even greater value to our customers and improved outcomes for patients.”

Ijaz Arif, CEO of VeeOne Health, added, “Equum Medical is an ideal home for VeeOne’s clinical services portfolio. Over the years, we have built robust telehealth programs that have made a real impact for our clients. Joining forces with Equum – a market leader in acute telehealth – means our customers will now benefit from a full spectrum of high-acuity telehealth solutions under one roof. Equum’s commitment to clinical quality and innovation mirrors our own, and we are confident that together, we will continue to provide exceptional virtual care services to healthcare organizations nationwide. This is a win for our clients and for the future of telehealth.” Following this transaction, VeeOne Health Inc. will continue to devote its focus on leading innovation in the virtual healthcare market, supporting healthcare organizations worldwide through its AI-based products to enhance patient care in areas such as remote patient monitoring (RPM), hospital at home, acute inpatient care, ambulatory services, care coordination, and virtual nursing.

Strategic Rationale and Impact:

The acquisition comes at a pivotal time in healthcare, as hospitals face persistent workforce shortages and a rising demand for specialized care. By integrating VeeOne’s tele-specialty services, Equum Medical strengthens its position as a one-stop solution for hospitals seeking to augment staff and expand specialist coverage through virtual care. Equum’s expanded service portfolio is designed to address hospital needs addressing patient flow and through this announcement now spans serviceability pillars of both Access and Capacity. The Access Suite including multi-specialty services of Tele-Stroke, Tele-Neurology, Tele-Psychiatry, Tele-Pulmonology, Tele-Infectious Disease, Tele-Cardiology, Tele-Nephrology, and high acuity physician services of Tele-Critical Care, and Tele-Hospitalist and a Capacity Suite including virtual nursing, virtual safety sitter and observation programs, and telemetry monitoring with extensions into post-acute with Remote Patient Monitoring.

Market Leadership:

This acquisition also highlights the strength of Equum Medical’s leadership team and market strategic position. Equum is included in Becker’s Hospital Review Top Telehealth Companies to Know and prior to the global HIMSS event in Las Vegas in March 2025, Equum Medical was recognized as the #1 Vendor by market research firm Black Book Market Research in Tele-Critical Care and Virtual Nursing Solutions as well as overall Outsourced Virtual Clinician Services. For the executive team, Dr. Scurlock is a national speaker at such events as American Telemedicine Association Annual Conference (NEXUS) and National Rural Health Association (NRHA) and was recognized as one of the Top Digital Health Leaders by Slice of Healthcare for his impactful work in virtual care while Kristen Lawton, MSN, RN Equum’s Chief Nursing Officer, was honored among Becker’s “Women in Health IT to Know” (2024). Under their leadership, Equum has cultivated a culture of clinical excellence and innovation – a culture that will extend to the integration of VeeOne’s services.

Media Contact:

Karsten Russell-Wood
Chief Marketing & Experience Officer
karsten.russell-wood@equummedical.com
(T) 410-409-7376

Press Kit & Further Information: Please visit the Equum Medical website at www.equummedical.com or contact our media relations team (marketing@equummedical.com) for more details.

About Equum Medical: Equum Medical is a technology-enabled inpatient clinical services company recognized for its comprehensive acute care portfolio, now with expanded coverage in Tele-Neurology, Stroke and Psychiatry. Equum leverages advanced telehealth technologies to enhance clinical access and optimize healthcare delivery across hospitals in the United States. By addressing workforce challenges and improving operational efficiency, Equum Medical empowers healthcare systems to elevate patient care, optimize leadership, and achieve positive clinical, operational, and financial outcomes. For more information, visit www.equummedical.com.

About VeeOne Health: Based in Roseville, CA, VeeOne Health is a global leader in the Virtual Care technology, and operations. Founded in 2016, VeeOne Health has the most advanced telemedicine solutions for the entire continuum of care – from acute care settings to outpatient and remote patient monitoring. For more information about VeeOne Health’s vision for the future of telemedicine see https://veeonehealth.com/

SOURCE: Equum Medical

View the original press release on ACCESS Newswire

CEPM offers enterprises a proactive approach to cloud optimization integrated into engineering workflows, and drives immediate savings and long-term efficiency.

NEW YORK, NY / ACCESS Newswire / May 21, 2025 / PointFive, a leading provider of innovative cloud efficiency solutions, announced the launch of Cloud Efficiency Posture Management (CEPM), a new category of cloud optimization technology designed for enterprise engineering and FinOps teams. Inspired by the Cloud Security Posture Management (CSPM), CEPM represents a shift from periodic cost reviews to an always-on, strategic discipline for managing cloud efficiency across an organization.

Traditional cloud cost management tools typically emphasize financial reporting and surface-level optimizations. They neglect deeper technical inefficiencies, resulting in missed opportunities and limited accountability from engineering teams. CEPM addresses this critical gap by proactively detecting hidden cloud waste, providing context, and actionable recommendations.

“We started PointFive to solve cloud inefficiency at its root – the technical, operational reasons – not just surface-level cost management,” said Alon Arvatz, CEO and Founder of PointFive. “Our new CEPM approach makes cloud efficiency as routine and automatic as cloud security, embedding ongoing optimization deeply into daily engineering processes. This shift is essential for enterprises to realize sustainable efficiency at scale.”

“When we started exploring CEPM across different cloud providers, we were struck by how profoundly each platform’s unique metrics influence efficiency,” said Dor Azouri, VP of Research at PointFive. “Traditional tools overlook this because their focus is surface-level visibility. With DeepWaste™, context is everything. The significant savings we uncovered were eye-opening.”

Key features of CEPM include:

• Deep Optimization Insights: Identifies subtle inefficiencies missed by traditional tools, providing actionable, engineer-friendly recommendations.

• Seamless Workflow Integration: Directly integrates widely-used engineering platforms like Jira and ServiceNow and communication platforms like Slack and Teams, embedding efficiency management into everyday tasks without disruption.

• Rapid ROI and Immediate Impact: Enterprises such as Blackhawk Network (BHN), E.ON, Elastic, and Fanatics have already seen increased efficiency and significant cost savings within weeks of deployment.

• Frictionless, Rapid Deployment: CEPM’s agentless architecture enables deployment in a single integration, providing immediate visibility into inefficiencies and opportunities.

• Unique Azure Insights and Expanded Multi-Cloud Optimization: PointFive fully supports Microsoft Azure, AWS, and GCP. The importance of CEPM becomes even more evident in multi-cloud environments, where each provider surfaces different metrics, cost structures, and usage patterns. Azure, for example, reveals inefficiencies that may never appear in AWS, making cross-cloud efficiency difficult to standardize manually. CEPM bridges these gaps. It automates the discovery of cloud-specific opportunities while providing a unified, organization-wide view of efficiency posture. Early Azure adopters have uncovered millions in savings from inefficiencies unique to Azure’s environment.

Customers like BHN have successfully streamlined cloud optimization practices through CEPM, fostering deeper engineering engagement and sustained cost efficiencies.

“Cloud optimization should not be a periodic task or reactive exercise,” Arvatz emphasized. “CEPM empowers engineering teams to continuously embed efficiency into daily operations. The result is sustainable cloud savings, improved reliability, and increased agility – delivering strategic value far beyond simple cost-cutting.”

To learn more about CEPM and how PointFive is redefining cloud optimization, visit www.pointfive.co.

About PointFive
PointFive delivers innovative cloud efficiency solutions for enterprise engineering and FinOps teams. Its Cloud Efficiency Posture Management (CEPM) platform offers deep, actionable insights, continuous optimization, and measurable outcomes, enabling enterprises to proactively manage cloud resources and achieve sustainable efficiency.

Media Contact:

Omri Hurwitz
omri@omrihurwitz.com

SOURCE: Pointfive

View the original press release on ACCESS Newswire

HOUSTON, TEXAS / ACCESS Newswire / May 21, 2025 / EON Resources Inc. (NYSE American:EONR) (“EON” or the “Company”) is an independent upstream energy company with oil and gas properties in the Permian Basin. Today, the Company posted an updated investor deck and the first quarter of 2025 earnings call deck to the Company’s website: https://www.eon-r.com/presentations.

About the Oil Field Property

In November 2023, the Company acquired LH Operating, LLC (“LHO”) including its holdings in New Mexico of oil and gas waterflood production comprising 13,700 contiguous leasehold acres, 342 producing wells and 207 injection wells situated on 20 federal and 3 state leases in the Grayburg-Jackson Oil Field. The Grayburg-Jackson Oil Field is located on the Northwest Shelf of the prolific Permian Basin in Eddy County, New Mexico.

Leasehold rights of LHO, now a wholly owned subsidiary of the Company, include the Seven Rivers, Queen, Grayburg and San Andres intervals that range from as shallow as 1,500 feet to 4,000 feet in depth. The December 2023 reserve report from our third-party engineer, William H. Cobb and Associates, Inc. (“Cobb”), reflects LHO to have proven reserves of approximately 15.4 million barrels of oil and 3.5 billion cubic feet of natural gas. The mapped original-oil-in-place (“OOIP”) in the LHO leasehold is approximately 876 million barrels of oil in the Grayburg and San Andres intervals and 80 million barrels in the Seven Rivers interval for a total OOIP of approximately 956,000,000 barrels of oil.

Our primary production is currently from the Seven Rivers zone. In addition to proven reserves, the Company believes it may access an additional 34 million barrels of oil by adding perforations in the Grayburg and San Andres formations. With proven oil reserves of over 15 million barrels, combined with the potential 34 million additional barrels from the Grayburg and San Andres zones, LHO should produce oil and a revenue stream for more than two decades with a low decline rate.

About EON Resources Inc.

EON is an independent upstream energy company focused on maximizing total returns to its shareholders through the development of onshore oil and natural gas properties in the United States. EON’s long-term goal is to maximize total shareholder value from a diversified portfolio of long-life oil and natural gas properties built through acquisition and through selective development, production enhancement, and other exploitation efforts on its oil and natural gas properties.

EON’s Class A Common Stock trades on the NYSE American Stock Exchange (NYSE American: EONR) and the Company’s public warrants trade on the NYSE American Stock Exchange (NYSE American: EONR WS). For more information on EON, please visit the Company’s website: https://eon-r.com/.

Forward-Looking Statements

This press release includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties that could cause actual results to differ materially from what is expected. Words such as “expects,” “believes,” “anticipates,” “intends,” “estimates,” “seeks,” “may,” “might,” “plan,” “possible,” “should” and variations and similar words and expressions are intended to identify such forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Such forward-looking statements relate to future events or future results, based on currently available information and reflect the Company’s management’s current beliefs. A number of factors could cause actual events or results to differ materially from the events and results discussed in the forward-looking statements. Important factors – including the availability of funds, the results of financing efforts and the risks relating to our business – that could cause actual results to differ materially from the Company’s expectations are disclosed in the Company’s documents filed from time to time on EDGAR (see www.edgar-online.com) and with the Securities and Exchange Commission (see www.sec.gov). Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Except as expressly required by applicable securities law, the Company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

Investor Relations

Michael J. Porter, President
PORTER, LEVAY & ROSE, INC.
mike@plrinvest.com

SOURCE: EON Resources Inc.

View the original press release on ACCESS Newswire

From Tax Bracket Adjustments to New Audit Priorities, Clear Start Tax Helps Taxpayers Navigate the Year’s Key IRS Changes

IRVINE, CALIFORNIA / ACCESS Newswire / May 21, 2025 / With major IRS updates rolling out in 2025, Clear Start Tax, a nationally recognized tax resolution firm, is helping Americans understand what these changes mean for their finances, tax returns, and audit exposure. While the IRS is expanding enforcement efforts, it’s also introducing key adjustments and opportunities that taxpayers should understand before they file.

From inflation adjustments to new enforcement priorities, Clear Start Tax breaks down what taxpayers need to know to stay informed and protected.

Preparing Taxpayers for 2025: Clear Start Tax’s Guide to IRS Changes

Clear Start Tax is helping taxpayers stay informed and prepared as the IRS rolls out several important policy changes for 2025. From updated tax brackets to expanded retirement limits, here’s what individuals and families need to know to plan ahead.

Inflation-Adjusted Tax Brackets and Standard Deductions

According to Clear Start Tax, to keep pace with rising costs, the IRS has increased tax bracket thresholds and standard deductions for 2025.

• Standard deduction increases:

  • Single filers: $15,000 (up from $14,600)

  • Married filing jointly: $30,000 (up from $29,200)

  • Heads of household: $22,500 (up from $21,900)

• Tax bracket adjustments:
  Income thresholds have been raised by roughly 2.8% to help taxpayers avoid being pushed into higher brackets due to inflation alone.

Retirement Contribution Limit Enhancements

Clear Start Tax shares good news for retirement savers: the IRS has raised contribution limits for 2025.

• 401(k), 403(b), 457 plans: $23,500 (up from $23,000)

• Catch-up contributions:

  • Age 50+: $7,500

  • New for ages 60-63: $11,250, bringing total potential contributions to $34,750

Estate and Gift Tax Exclusion Increase

Families making long-term plans will benefit from expanded limits:

• Individuals: $13.99 million (up from $13.61 million)

• Married couples: $27.98 million

Expanded IRS Direct File Program

More taxpayers now have access to free IRS filing options:

• Available in 24 states

• Now covers taxpayers with 1099 income and credits like the Child and Dependent Care Credit

Increased Focus on High-Income Audits

Clear Start Tax warns that IRS enforcement will increasingly target:

• High-income households

• Cryptocurrency transactions

• Small businesses claiming large deductions

This shift makes careful tax preparation, documentation, and professional guidance more important than ever.

“Understanding these updates is critical to making informed tax decisions and avoiding surprises,” said the Head of Client Solutions at Clear Start Tax. “We help our clients navigate these new rules, protect their finances, and stay compliant with confidence.”

How Clear Start Tax Helps Taxpayers Stay Prepared

With new policies come new risks-and opportunities. Clear Start Tax provides:

• Personalized financial reviews to assess impact

• Guidance on selecting the right IRS relief programs

• Expert negotiation and communication with the IRS

• Ongoing compliance support to avoid penalties or audits

About Clear Start Tax

Clear Start Tax is a full-service tax liability resolution firm that serves taxpayers throughout the United States. The company specializes in assisting individuals and businesses with a wide range of IRS and state tax issues, including back taxes, wage garnishment relief, IRS appeals, and offers in compromise. Clear Start Tax helps taxpayers apply for the IRS Fresh Start Program, providing expert guidance in tax resolution. Fully accredited and A+ rated by the Better Business Bureau, the firm’s unique approach and commitment to long-term client success distinguish it as a leader in the tax resolution industry.

Need Help With Back Taxes?

Click the link below:
https://clearstarttax.com/qualifytoday/

Contact Information

Clear Start Tax
Corporate Communications Department
seo@clearstarttax.com
(949) 535-1627

SOURCE: Clear Start Tax

View the original press release on ACCESS Newswire

SAN FRANCISCO, CA / ACCESS Newswire / May 21, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) (“Jaguar” or “the Company”), today announced that it has entered into definitive agreements for the purchase and sale of 246,306 shares of common stock at a purchase price of $6.09 per share in a registered direct offering priced at-the-market under Nasdaq rules. In a concurrent private placement, the Company agreed to issue to investors unregistered warrants to purchase up to 492,612 shares of common stock at an exercise price of $5.84 per share that will be immediately exercisable upon issuance and will expire on the earlier of (i) 24 months from the date of issuance, (ii) the consummation of a fundamental transaction and (iii) the consummation of a liquidation event. The closing of the offering is expected to occur on or about May 22, 2025, subject to the satisfaction of customary closing conditions.

H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.

The gross proceeds to the Company from the offering are expected to be approximately $1.5 million before deducting placement agent fees and other offering expenses payable by the Company. The Company intends to use the net proceeds from the offering for general corporate purposes, including growth capital, working capital, operating expenses, repayment of outstanding convertible promissory notes that are not converted into Common Stock by holders, and capital expenditures.

The common stock (but not the unregistered warrants and the shares of common stock underlying the unregistered warrants) described above are being offered by the Company pursuant to a “shelf” registration statement on Form S-3 (File No. 333-278861) that was declared effective by the Securities and Exchange Commission (the “SEC”) on May 1, 2024. The offering of the shares of common stock is being made only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement. A final prospectus supplement and accompanying prospectus relating to the registered direct offering will be filed with the SEC. Electronic copies of the final prospectus supplement and accompanying prospectus may be obtained, when available, on the SEC’s website at http://www.sec.gov or by contacting H.C. Wainwright & Co., LLC at 430 Park Avenue, 3rd Floor, New York, New York 10022, by phone at (212) 856-5711 or e-mail at placements@hcwco.com.

The unregistered warrants described above are being offered in a private placement under Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), and/or Regulation D promulgated thereunder and, along with the shares of common stock underlying such unregistered warrants, have not been registered under the Securities Act, or applicable state securities laws. Accordingly, the unregistered warrants and underlying shares of common stock may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About the Jaguar Health Family of Companies

Jaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, bowel incontinence, and cramping pain. Jaguar family company Napo Pharmaceuticals (Napo) focuses on developing and commercializing human prescription pharmaceuticals for essential supportive care and management of neglected gastrointestinal symptoms across multiple complicated disease states. Napo’s crofelemer is FDA-approved under the brand name Mytesi^® for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. Jaguar family company Napo Therapeutics is an Italian corporation Jaguar established in Milan, Italy in 2021 focused on expanding crofelemer access in Europe and specifically for orphan and/or rare diseases. Jaguar Animal Health is a Jaguar tradename. Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health Corp. that emerged from Jaguar’s Entheogen Therapeutics Initiative (ETI), is focused on developing novel prescription medicines derived from plants for mental health indications.

For more information about:

Jaguar Health, visit https://jaguar.health

Napo Pharmaceuticals, visit www.napopharma.com

Napo Therapeutics, visit napotherapeutics.com

Magdalena Biosciences, visit magdalenabiosciences.com

Visit the Make Cancer Less Shitty patient advocacy program on Bluesky, X, Facebook & Instagram

Forward-Looking Statements

Certain statements in this press release constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. These include statements regarding the expected closing of the offering, the intended use of proceeds from the offering, and the Company’s expectations for future development, operations, business strategies and financial performance. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “aim,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar’s control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

Contact:

hello@jaguar.health
Jaguar-JAGX

SOURCE: Jaguar Health, Inc.

View the original press release on ACCESS Newswire

AUSTIN, TEXAS / ACCESS Newswire / May 21, 2025 / Interactive Strength Inc. (Nasdaq:TRNR) (“TRNR” or the “Company”), maker of innovative specialty fitness equipment under the CLMBR and FORME brands and pending acquirer of Sportstech and Wattbike, today announced that it has updated its investor FAQ’s on its investor website in response to shareholder questions around its AGM date and other corporate actions.

For more commentary, information and details on the rationale for and structure of the expected acquisitions, please see TRNR’s investor presentation on the Company’s investor website as well as its required filings with the US Securities & Exchange Commission (SEC).

TRNR Investor Contact
ir@interactivestrength.com

About Interactive Strength Inc.:

Interactive Strength Inc. produces innovative specialty fitness equipment and digital fitness services under two main brands: 1) CLMBR and 2) FORME. Interactive Strength Inc. is listed on NASDAQ (symbol:TRNR).

CLMBR is a vertical climbing machine that offers an efficient and effective full-body strength and cardio workout. CLMBR’s design is compact and easy to move – making it perfect for commercial or in-home use. With its low impact and ergonomic movement, CLMBR is safe for most ages and levels of ability and can be found at gyms and fitness studios, hotels, and physical therapy facilities, as well as available for consumers at home. www.clmbr.com.

FORME is a digital fitness platform that combines premium smart gyms with live virtual personal training and coaching to deliver an immersive experience and better outcomes for both consumers and trainers. FORME delivers an immersive and dynamic fitness experience through two connected hardware products: 1) The FORME Studio Lift (fitness mirror and cable-based digital resistance) and 2) The FORME Studio (fitness mirror). In addition to the company’s connected fitness hardware products, FORME offers expert personal training and health coaching in different formats and price points through Video On-Demand, Custom Training, and Live 1:1 virtual personal training. www.formelife.com.

Forward Looking Statements:
This press release includes certain statements that are “forward-looking statements” for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements do not relate strictly to historical or current facts and reflect management’s assumptions, views, plans, objectives and projections about the future. Forward-looking statements generally are accompanied by words such as “believe”, “project”, “expect”, “anticipate”, “estimate”, “intend”, “strategy”, “future”, “opportunity”, “plan”, “may”, “should”, “will”, “would”, “will be”, “will continue”, “will likely result” or similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding the possibility of acquiring future businesses or completing the referenced pending transactions in a timely manner or at all, the financial performance of those acquisitions and the resulting guidance of having more than $75m of pro forma revenue in 2025, achieving profitability by Q4, and the financial performance of the acquisition targets which have not been audited or reviewed by a PCAOB auditor and could vary materially (a) once that audit or review work is completed and such financials are included in the Company’s reported financials and (b) due to the effect of the exchange rates of foreign currencies which can be volatile. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of the Company. Risks and uncertainties include but are not limited to: demand for our products; competition, including technological advances made by and new products released by our competitors; our ability to accurately forecast consumer demand for our products and adequately maintain our inventory; and our reliance on a limited number of suppliers and distributors for our products. A further list and descriptions of these risks, uncertainties and other factors can be found in filings with the Securities and Exchange Commission. To the extent permitted under applicable law, the Company assumes no obligation to update any forward-looking statements.

# # #

SOURCE: Interactive Strength Inc.

View the original press release on ACCESS Newswire

NEWARK, CA / ACCESS Newswire / May 21, 2025 / Protagonist Therapeutics, Inc. (“Protagonist” or the “Company”) today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will present a company overview at the Jefferies Global Healthcare Conference taking place June 3-5, 2025, in New York, NY. The Company will also participate in one-on-one meetings.

Jefferies Global Healthcare Conference – June 3-5, 2025

Format: Company Presentation
Day/Time: Wednesday, June 4 at 1:25 P.M. ET
Webcast: https://wsw.com/webcast/jeff319/ptgx/1883080

If you are interested in meeting with the Protagonist team during the conference, please reach out to your Jefferies representative.

A replay of the presentation will be available on the Company’s Investor Relations Events and Presentations webpage for one year following the event.

About Protagonist
Protagonist Therapeutics is a discovery through late-stage development biopharmaceutical company. Two novel peptides, icotrokinra and rusfertide, derived from Protagonist’s proprietary discovery platform are currently in advanced Phase 3 clinical development, with New Drug Application submissions to the FDA expected in 2025. Icotrokinra (JNJ-2113) is a first-in-class investigational targeted oral peptide that selectively blocks the Interleukin-23 receptor (“IL-23R”) which is licensed to Janssen Biotech, Inc., a Johnson & Johnson company. Following icotrokinra’s joint discovery by Protagonist and Johnson & Johnson scientists pursuant to the companies’ IL-23R collaboration, Protagonist was primarily responsible for development of icotrokinra through Phase 1, with Johnson & Johnson assuming responsibility for development in Phase 2 and beyond. Rusfertide, a mimetic of the natural hormone hepcidin, is currently in Phase 3 development for the rare blood disorder polycythemia vera (PV). Rusfertide is being co-developed and will be co-commercialized with Takeda Pharmaceuticals pursuant to a worldwide collaboration and license agreement entered into in 2024 under which the Company remains primarily responsible for development through NDA filing. The Company also has a number of pre-clinical stage oral drug discovery programs addressing clinically and commercially validated targets, including the IL-17 oral peptide antagonist PN-881, an oral hepcidin program, and an oral obesity program.

More information on Protagonist, its pipeline drug candidates and clinical studies can be found on the Company’s website at www.protagonist-inc.com.

Investor Relations Contact
Corey Davis, Ph.D.
LifeSci Advisors
+1 212 915 2577
cdavis@lifesciadvisors.com

Media Contact
Virginia Amann, Founder/CEO
+1 833 500 0061 ext 1
ENTENTE Network of Companies
virginiaamann@ententeinc.com

SOURCE: Protagonist Therapeutics

View the original press release on ACCESS Newswire

Company successfully completes major equipment and process flow testing for the commercial design of its large-scale boron facility

5E’s project advancements positions the United States to maintain position of strength in the global boron supply chain and disrupt the global boron market oligopoly

HESPERIA, CA / ACCESS Newswire / May 21, 2025 / 5E Advanced Materials, Inc. (Nasdaq:FEAM)(ASX:5EA) (“5E” or the “Company”), a boron and lithium company with U.S. government Critical Infrastructure designation for its 5E Boron Americas Complex, today announced that it has achieved another developmental milestone, completing equipment testing for all major processes of the commercial design for its large-scale boron facility. This disciplined approach now enables 5E to focus and transition the team’s efforts towards updating the Company’s technical report summary in the near term.

“Over the past three months, 5E and our EPC-partner Fluor have coordinated with various equipment manufacturers, third-party laboratories and our Small-Scale Facility team to test various aspects of our commercial design,” stated Paul Weibel, Chief Executive Officer. “The testing has included crystallization, metal impurity removal, centrifuges, filtration, reverse osmosis, membrane technology, and dryer packages. As expected, our testing was highly successful and the results of which now position the Company to update our technical report summary and initiate a smooth transition to FEED engineering. We believe the successful testing at this phase in the process will carry significant merit during our project financing diligence as we position the Company to break up the global boron market’s oligopoly. Our success will ensure that the United States no longer has a single point of supply chain failure and maintains a position of strength in the global boron market.”

About 5E Advanced Materials, Inc.

5E Advanced Materials, Inc. (NASDAQ: FEAM) (ASX:5EA) is focused on becoming a vertically integrated global leader and supplier of boron specialty and advanced materials, complemented by lithium co-product production. The Company’s mission is to become a supplier of these critical materials to industries addressing global decarbonization, food and domestic security. Boron and lithium products will target applications in the fields of electric transportation, clean energy infrastructure, such as solar and wind power, fertilizers, and domestic security. The business strategy and objectives are to develop capabilities ranging from upstream extraction and product sales of boric acid, lithium carbonate and potentially other co-products, to downstream boron advanced material processing and development. The business is based on our large domestic boron and lithium resource, which is located in Southern California and designated as Critical Infrastructure by the Department of Homeland Security’s Cybersecurity and Infrastructure Security Agency.

Forward Looking Statements

This press release includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. All statements other than statements of historical fact included in this press release regarding the Company’s business strategy, plans, goals, and objectives, including regarding the expected closing date of the private placement transaction and the anticipated benefits of the private placement transaction, are forward-looking statements. When used in this press release, the words “believe,” “project,” “expect,” “forecast,” “anticipate,” “estimate,” “intend,” “seek,” “budget,” “target,” “aim,” “strategy,” “plan,” “guidance,” “outlook,” “intent,” “may,” “should,” “could,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain such identifying words. These forward-looking statements are based on the Company’s current expectations and assumptions about future events and are based on currently available information as to the outcome and timing of future events. We caution you that these forward-looking statements are subject to all of the risks and uncertainties, most of which are difficult to predict and many of which are beyond our control, incident to the extraction of the critical materials we intend to produce and advanced materials production and development. These risks include, but are not limited to: our limited operating history in the borates and lithium industries and no revenue from our proposed extraction operations at our properties; our need for substantial additional financing to continue as a going concern and to execute our business plan and our ability to access capital and the financial markets; our status as an exploration stage company dependent on a single project with no known Regulation S-K 1300 mineral reserves and the inherent uncertainty in estimates of mineral resources; our lack of history in mineral production and the significant risks associated with achieving our business strategies, including our downstream processing ambitions; our incurrence of significant net operating losses to date and plans to incur continued losses for the foreseeable future; risks and uncertainties relating to the development of the Fort Cady project, including our ability to timely and successfully complete our proposed Commercial Scale Boron Facility, and related matters on a timely manner or at all; our ability to obtain, maintain and renew required governmental permits for our development activities, including satisfying all mandated conditions to any such permits; the implementation of and expected benefits from certain reduced spending measures; and other risks and uncertainties set forth in our filings with the U.S. Securities and Exchange Commission from time to time. Should one or more of these risks or uncertainties occur, or should underlying assumptions prove incorrect, our actual results and plans could differ materially from those expressed in any forward-looking statements. These risks are not exhaustive and the information in this press release may be subject to additional risks. No representation or warranty (express or implied) is made as to, and no reliance should be placed on, any information, including projections, estimates, targets, and opinions contained herein, and no liability whatsoever is accepted as to any errors, omissions, or misstatements contained herein. You are cautioned not to place undue reliance on any forward-looking statements, which speak only as to the date of this press release.

For additional information regarding these various factors, you should carefully review the risk factors and other disclosures in the Company’s Form 10-K filed on September 9, 2024 and subsequent filings with the U.S. Securities and Exchange Commission, as well as in its filings under the Australian Securities Exchange. Any forward-looking statements are given only as of the date hereof. Except as required by law, 5E expressly disclaims any obligation to update or revise any such forward-looking statements. Additionally, 5E undertakes no obligation to comment on third party analyses or statements regarding 5E’s actual or expected financial or operating results or its securities.

For further information contact:

Nathan Skown or Joseph Caminiti
Alpha IR Group
FEAM@alpha-ir.com
Ph: +1 (312) 445-2870

SOURCE: 5E Advanced Materials, Inc.

View the original press release on ACCESS Newswire